CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: METTL16 (ImmuneEditome ID:79066)

1. Gene summary of enriched editing regions for METTL16

check button Gene summary
Gene informationGene symbol

METTL16

Gene ID

79066

GeneSynonymsMETT10D
GeneCytomap

17p13.3

GeneTypeprotein-coding
GeneDescriptionRNA N6-adenosine-methyltransferase METTL16|N6-adenosine-methyltransferase METTL16|N6-methyladenosine methyltransferase|U6 small nuclear RNA (adenine-(43)-N(6))-methyltransferase|U6 snRNA methyltransferase|methyltransferase 10 domain containing|methyltransferase 10 domain-containing protein|methyltransferase 16, N6-methyladenosine|methyltransferase like 16|methyltransferase-like protein 16|putative methyltransferase METT10D
GeneModificationdate20230524
UniprotIDQ86W50;I3L3W3;I3L4V1;I3L362
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:2417087-2418556:-ENST00000571669.5ENSG00000127804.11METTL16ncRNA_exonic(AC)n,Charlie4z,AluSx,AluSq,L1ME4achr17:2417087-2418556:-.alignment
chr17:2471225-2472041:-ENST00000571669.5ENSG00000127804.11METTL16ncRNA_intronicAluY,AluSz,AluSq2chr17:2471225-2472041:-.alignment


Top

2. Tumor-specific enriched editing regions for METTL16


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr17:2417087-2418556:-BRCAEER4.3613e-04image
ENSG00000127804.11,METTL16BRCAEAG2.9702e-04image
chr17:2417087-2418556:-KIRPEER3.5166e-02image
ENSG00000127804.11,METTL16KIRPEAG2.8200e-02image
chr17:2417087-2418556:-LUSCEER2.8511e-06image
ENSG00000127804.11,METTL16LUSCEAG1.0574e-06image
chr17:2417087-2418556:-THCAEER4.1241e-02image
ENSG00000127804.11,METTL16THCAEAG4.5586e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for METTL16


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:2417087-2418556:-GBMEERENSG00000159176,CSRP10.30884.9532e-035.4161e-090.4359imageNNNAPlasma_cellsGSVA_HALLMARK_BILE_ACID_METABOLISM
chr17:2417087-2418556:-GBMEERENSG00000012223,LTF0.23914.4984e-022.9230e-100.4670imageNNLTFPlasma_cellsGSVA_HALLMARK_XENOBIOTIC_METABOLISM
chr17:2417087-2418556:-LAMLEERENSG00000178429,RPS3AP50.35584.8828e-026.5044e-070.4246imageNNNAEosinophilsGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr17:2417087-2418556:-UVMEERENSG00000100320,RBFOX2-0.65975.4324e-065.6131e-09-0.5956imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr17:2417087-2418556:-UVMEERENSG00000143252,SDHC-0.65555.4324e-069.6652e-08-0.5542imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr17:2417087-2418556:-UVMEERENSG00000103342,GSPT1-0.65507.8593e-068.3054e-10-0.6205imageNNGSPT1T_cells_follicular_helperGSVA_HALLMARK_ANDROGEN_RESPONSE
chr17:2417087-2418556:-UVMEERENSG00000066777,ARFGEF1-0.64827.8593e-061.3116e-06-0.5105imageNNARFGEF1T_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr17:2417087-2418556:-UVMEERENSG00000104388,RAB2A-0.64248.1595e-062.1743e-06-0.5013imageNNNAT_cells_follicular_helperGSVA_HALLMARK_MTORC1_SIGNALING
chr17:2417087-2418556:-UVMEERENSG00000230409,TCEA1P2-0.65098.3488e-062.3112e-07-0.5403imageNNNAT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr17:2417087-2418556:-UVMEERENSG00000140157,NIPA2-0.64619.4479e-062.5642e-08-0.5742imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

4. Enriched editing regions and immune related splicing for METTL16


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:2417087-2418556:-
GBMEERESENSG00000213995.7chr13110624233:110624279:110625189:110625278:110627438:1106275470.37899.1104e-041.8042e-070.4008imageNNNAMacrophages_M0GSVA_HALLMARK_BILE_ACID_METABOLISM
chr17:2417087-2418556:-
KIRCEERMEXENSG00000129657.10chr1777216098:77216101:77216127:77216166:77216166:77216296:77216335:772163480.18821.4709e-036.5462e-150.4004imageNNNAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000127804.11,METTL16
KIRCEAGMEXENSG00000129657.10chr1777216098:77216101:77216127:77216166:77216166:77216296:77216335:772163480.19279.9815e-044.7776e-150.4023imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chr17:2417087-2418556:-
TGCTEERESENSG00000198917.7chr9128822797:128822833:128823746:128823863:128824071:1288241740.30321.9135e-039.4385e-070.4352imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS
ENSG00000127804.11,METTL16
TGCTEAGESENSG00000126746.13chr126670759:6670838:6672349:6672532:6673215:66733950.41421.2421e-045.7057e-080.4191imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
chr17:2417087-2418556:-
TGCTEERA3ENSG00000122515.10chr744756409:44756539:44756946:44757050:44757042:44757050-0.31228.0795e-034.3032e-10-0.4921imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE
ENSG00000127804.11,METTL16
TGCTEAGESENSG00000088305.14chr2032792625:32792770:32793535:32793595:32795408:32795534-0.32241.8037e-032.5893e-06-0.4063imageNACIN1;ADAR;AIFM1;AUH;BCCIP;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000127804.11,METTL16
TGCTEAGA5ENSG00000126746.13chr126670759:6670838:6673215:6673395:6672349:6673395-0.43993.3448e-051.8476e-08-0.4329imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MTORC1_SIGNALING
ENSG00000127804.11,METTL16
TGCTEAGIRENSG00000126088.8chr145013135:45013354:45013574:450136950.26681.7076e-025.4768e-060.4031imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAB_cells_naiveGSVA_HALLMARK_GLYCOLYSIS
chr17:2417087-2418556:-
TGCTEERESENSG00000204120.10chr2232697382:232697392:232700584:232700654:232703423:232703489-0.31601.5705e-035.8493e-08-0.4834imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_GLYCOLYSIS

More results



Top

5. Enriched editing regions and immune infiltration for METTL16


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:2417087-2418556:-ACCEERPlasma_cells1.3187e-020.2813image
ENSG00000127804.11,METTL16ACCEAGPlasma_cells1.3187e-020.2813image
chr17:2417087-2418556:-BLCAEEREosinophils6.9469e-030.1354image
ENSG00000127804.11,METTL16BLCAEAGEosinophils6.7503e-030.1359image
chr17:2417087-2418556:-BRCAEERMacrophages_M11.0691e-020.0778image
ENSG00000127804.11,METTL16BRCAEAGMacrophages_M16.6897e-030.0826image
chr17:2417087-2418556:-CESCEERMast_cells_activated2.8429e-020.1268image
ENSG00000127804.11,METTL16CESCEAGMast_cells_activated2.7976e-020.1271image
chr17:2417087-2418556:-CHOLEERMacrophages_M13.5850e-030.4858image
ENSG00000127804.11,METTL16CHOLEAGMacrophages_M13.5850e-030.4858image
chr17:2417087-2418556:-COADEERNeutrophils1.4745e-030.1970image
ENSG00000127804.11,METTL16COADEAGNeutrophils1.3786e-030.1974image
chr17:2417087-2418556:-ESCAEERMacrophages_M09.1465e-030.2048image
ENSG00000127804.11,METTL16ESCAEAGMacrophages_M09.2526e-030.2045image
chr17:2417087-2418556:-GBMEERPlasma_cells4.9279e-050.3114image
ENSG00000127804.11,METTL16GBMEAGPlasma_cells4.6668e-050.3123image
chr17:2417087-2418556:-HNSCEERNeutrophils1.6316e-020.1079image
ENSG00000127804.11,METTL16HNSCEAGT_cells_CD4_memory_activated1.6709e-020.1075image
chr17:2417087-2418556:-KIRCEERB_cells_memory4.4571e-060.2332image
ENSG00000127804.11,METTL16KIRCEAGB_cells_memory4.2894e-060.2336image
chr17:2417087-2418556:-KIRPEERT_cells_CD4_naive5.2581e-070.2919image
ENSG00000127804.11,METTL16KIRPEAGT_cells_CD4_naive1.5478e-070.3047image
chr17:2417087-2418556:-LAMLEERMacrophages_M12.3236e-020.2013image
ENSG00000127804.11,METTL16LAMLEAGMacrophages_M11.4255e-020.2162image
chr17:2417087-2418556:-LGGEERMacrophages_M05.0496e-03-0.1217image
ENSG00000127804.11,METTL16LGGEAGMacrophages_M04.9367e-03-0.1220image
chr17:2417087-2418556:-LIHCEERT_cells_gamma_delta3.2432e-02-0.1293image
ENSG00000127804.11,METTL16LIHCEAGT_cells_gamma_delta3.3137e-02-0.1288image
chr17:2417087-2418556:-LUADEERT_cells_CD4_memory_activated2.5305e-030.1353image
ENSG00000127804.11,METTL16LUADEAGT_cells_CD4_memory_activated3.2225e-030.1319image
chr17:2417087-2418556:-LUSCEERT_cells_CD4_memory_resting7.8253e-03-0.1204image
ENSG00000127804.11,METTL16LUSCEAGT_cells_CD4_memory_resting4.3648e-03-0.1290image
chr17:2417087-2418556:-OVEERT_cells_CD87.5879e-040.1970image
ENSG00000127804.11,METTL16OVEAGT_cells_CD88.9632e-040.1943image
chr17:2417087-2418556:-PAADEERMast_cells_activated4.9992e-02-0.1493image
ENSG00000127804.11,METTL16PAADEAGMast_cells_activated4.9427e-02-0.1496image
chr17:2417087-2418556:-PCPGEERT_cells_CD4_memory_activated1.0284e-020.1908image
ENSG00000127804.11,METTL16PCPGEAGT_cells_CD4_memory_activated1.4905e-020.1812image
chr17:2417087-2418556:-PRADEERMacrophages_M24.3471e-030.1277image
ENSG00000127804.11,METTL16PRADEAGMacrophages_M25.2145e-030.1251image
chr17:2417087-2418556:-READEERT_cells_CD4_naive1.3650e-020.2550image
ENSG00000127804.11,METTL16READEAGT_cells_CD4_naive1.3652e-020.2550image
chr17:2417087-2418556:-SARCEERDendritic_cells_activated1.1941e-020.1572image
ENSG00000127804.11,METTL16SARCEAGDendritic_cells_activated1.0609e-020.1598image
chr17:2417087-2418556:-SKCMEERT_cells_regulatory_(Tregs)6.3032e-030.1260image
ENSG00000127804.11,METTL16SKCMEAGT_cells_regulatory_(Tregs)6.7459e-030.1249image
chr17:2417087-2418556:-STADEERB_cells_memory1.8123e-03-0.1625image
ENSG00000127804.11,METTL16STADEAGB_cells_memory1.5265e-03-0.1651image
chr17:2417087-2418556:-TGCTEERNeutrophils2.7304e-070.3977image
ENSG00000127804.11,METTL16TGCTEAGNeutrophils2.1956e-070.4006image
chr17:2417087-2418556:-THCAEERMast_cells_activated1.0490e-02-0.1139image
ENSG00000127804.11,METTL16THCAEAGMast_cells_activated1.1053e-02-0.1131image
chr17:2417087-2418556:-THYMEERMacrophages_M26.1393e-030.2509image
ENSG00000127804.11,METTL16THYMEAGMacrophages_M28.6455e-030.2407image
chr17:2417087-2418556:-UVMEERT_cells_CD84.7040e-03-0.3130image
ENSG00000127804.11,METTL16UVMEAGT_cells_CD84.9569e-03-0.3112image


Top

6. Enriched editing regions and immune gene sets for METTL16


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000127804.11,METTL16UVMEAG4.2060e-06-0.48891.3486e-05-0.46562.0253e-06-0.50264.2399e-02-0.2275image
chr17:2417087-2418556:-UVMEER3.7716e-06-0.49109.5880e-06-0.47261.6065e-06-0.50694.8203e-02-0.2216image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr17:2417087-2418556:-BLCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.1651e-020.1154image
ENSG00000127804.11,METTL16BLCAGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.0042e-020.1168image
ENSG00000127804.11,METTL16BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.1363e-080.1651image
chr17:2417087-2418556:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7377e-070.1560image
chr17:2417087-2418556:-CESCGSVA_HALLMARK_NOTCH_SIGNALINGEER9.4824e-030.1498image
ENSG00000127804.11,METTL16CESCGSVA_HALLMARK_NOTCH_SIGNALINGEAG9.2961e-030.1502image
ENSG00000127804.11,METTL16CHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.2106e-020.4255image
chr17:2417087-2418556:-CHOLGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.2106e-020.4255image
ENSG00000127804.11,METTL16COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG4.7306e-02-0.1231image
ENSG00000127804.11,METTL16ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0551e-030.2253image
chr17:2417087-2418556:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.6982e-030.2218image
chr17:2417087-2418556:-GBMGSVA_HALLMARK_MYC_TARGETS_V2EER2.3413e-05-0.3238image
ENSG00000127804.11,METTL16GBMGSVA_HALLMARK_MYC_TARGETS_V2EAG2.0166e-05-0.3262image
ENSG00000127804.11,METTL16HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4581e-020.1097image
chr17:2417087-2418556:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5119e-020.1092image
ENSG00000127804.11,METTL16KICHGSVA_HALLMARK_DNA_REPAIREAG1.0817e-02-0.3142image
chr17:2417087-2418556:-KICHGSVA_HALLMARK_DNA_REPAIREER1.0295e-02-0.3162image
ENSG00000127804.11,METTL16KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG4.3709e-02-0.1037image
chr17:2417087-2418556:-KIRCGSVA_HALLMARK_TGF_BETA_SIGNALINGEER3.6735e-02-0.1073image
chr17:2417087-2418556:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER3.4877e-03-0.1725image
ENSG00000127804.11,METTL16KIRPGSVA_HALLMARK_UV_RESPONSE_DNEAG1.9928e-03-0.1824image
ENSG00000127804.11,METTL16LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.9217e-04-0.3087image
chr17:2417087-2418556:-LAMLGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.6420e-04-0.3283image
ENSG00000127804.11,METTL16LGGGSVA_HALLMARK_MYC_TARGETS_V2EAG7.9049e-08-0.2308image
chr17:2417087-2418556:-LGGGSVA_HALLMARK_MYC_TARGETS_V2EER1.5669e-07-0.2256image
ENSG00000127804.11,METTL16LIHCGSVA_HALLMARK_DNA_REPAIREAG2.3980e-04-0.2202image
chr17:2417087-2418556:-LIHCGSVA_HALLMARK_DNA_REPAIREER2.2290e-04-0.2213image
chr17:2417087-2418556:-LUADGSVA_HALLMARK_ANGIOGENESISEER4.0097e-040.1583image
ENSG00000127804.11,METTL16LUADGSVA_HALLMARK_ANGIOGENESISEAG3.5424e-040.1596image
chr17:2417087-2418556:-LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEER7.7403e-03-0.1206image
ENSG00000127804.11,METTL16LUSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.7192e-03-0.1187image
ENSG00000127804.11,METTL16OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.8783e-050.2341image
chr17:2417087-2418556:-OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.7993e-050.2398image
chr17:2417087-2418556:-PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.1216e-020.1639image
ENSG00000127804.11,METTL16PAADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.3604e-020.1616image
ENSG00000127804.11,METTL16PRADGSVA_HALLMARK_MYC_TARGETS_V2EAG6.5188e-03-0.1219image
chr17:2417087-2418556:-PRADGSVA_HALLMARK_MYC_TARGETS_V2EER2.1936e-03-0.1371image
chr17:2417087-2418556:-READGSVA_HALLMARK_E2F_TARGETSEER1.6948e-020.2471image
ENSG00000127804.11,METTL16READGSVA_HALLMARK_E2F_TARGETSEAG1.7786e-020.2453image
chr17:2417087-2418556:-SARCGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.9135e-02-0.1466image
ENSG00000127804.11,METTL16SARCGSVA_HALLMARK_HYPOXIAEAG1.9108e-020.1467image
ENSG00000127804.11,METTL16SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.2502e-04-0.1653image
chr17:2417087-2418556:-SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER2.9918e-04-0.1662image
chr17:2417087-2418556:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.4875e-050.2184image
ENSG00000127804.11,METTL16STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1514e-050.2157image
chr17:2417087-2418556:-TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEER1.0289e-04-0.3059image
ENSG00000127804.11,METTL16TGCTGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.0378e-04-0.3058image
chr17:2417087-2418556:-THCAGSVA_HALLMARK_PROTEIN_SECRETIONEER3.4253e-040.1589image
ENSG00000127804.11,METTL16THCAGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.6956e-04-0.1580image
chr17:2417087-2418556:-THYMGSVA_HALLMARK_NOTCH_SIGNALINGEER6.9192e-030.2474image
ENSG00000127804.11,METTL16THYMGSVA_HALLMARK_NOTCH_SIGNALINGEAG9.8095e-030.2369image
chr17:2417087-2418556:-UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.8554e-030.3670image
ENSG00000127804.11,METTL16UCSGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.3126e-030.3578image
chr17:2417087-2418556:-UVMGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.8210e-08-0.5792image
ENSG00000127804.11,METTL16UVMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.3071e-08-0.5758image


Top

7. Enriched editing regions and drugs for METTL16


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:2417087-2418556:-BLCAAZD6482EER1.2670e-02-0.1252image
ENSG00000127804.11,METTL16BLCAAZD6482EAG1.1096e-02-0.1275image
ENSG00000127804.11,METTL16BRCAFH535EAG4.6148e-040.1066image
chr17:2417087-2418556:-BRCAFH535EER8.2885e-040.1018image
ENSG00000127804.11,METTL16CESCGDC.0449EAG2.7905e-020.1272image
chr17:2417087-2418556:-CESCGDC.0449EER2.8204e-020.1269image
ENSG00000127804.11,METTL16CHOLA.443654EAG3.9773e-030.4810image
chr17:2417087-2418556:-CHOLA.443654EER3.9773e-030.4810image
chr17:2417087-2418556:-COADBMS.708163EER2.0472e-02-0.1442image
ENSG00000127804.11,METTL16COADBMS.708163EAG1.2329e-02-0.1550image
ENSG00000127804.11,METTL16DLBCLenalidomideEAG2.5149e-03-0.4263image
chr17:2417087-2418556:-DLBCLenalidomideEER3.3511e-03-0.4151image
chr17:2417087-2418556:-ESCACGP.60474EER1.8853e-03-0.2431image
ENSG00000127804.11,METTL16ESCACGP.60474EAG2.2877e-03-0.2388image
chr17:2417087-2418556:-GBMBI.2536EER1.0234e-050.3370image
ENSG00000127804.11,METTL16GBMBI.2536EAG7.2209e-060.3424image
chr17:2417087-2418556:-HNSCGNF.2EER3.5387e-030.1313image
ENSG00000127804.11,METTL16HNSCGNF.2EAG3.5449e-030.1312image
ENSG00000127804.11,METTL16KICHAS601245EAG4.5429e-020.2491image
chr17:2417087-2418556:-KICHAS601245EER4.4530e-020.2501image
chr17:2417087-2418556:-KIRCBexaroteneEER1.1414e-060.2469image
ENSG00000127804.11,METTL16KIRCBexaroteneEAG8.8392e-070.2493image
chr17:2417087-2418556:-KIRPFTI.277EER3.0423e-040.2124image
ENSG00000127804.11,METTL16KIRPFTI.277EAG9.9963e-050.2284image
ENSG00000127804.11,METTL16LAMLCisplatinEAG1.8084e-02-0.2087image
chr17:2417087-2418556:-LAMLCisplatinEER9.1535e-03-0.2304image
ENSG00000127804.11,METTL16LGGEpothilone.BEAG4.7512e-110.2809image
chr17:2417087-2418556:-LGGEpothilone.BEER5.9673e-110.2795image
ENSG00000127804.11,METTL16LIHCBMS.509744EAG9.0800e-050.2342image
chr17:2417087-2418556:-LIHCBMS.509744EER8.6199e-050.2350image
chr17:2417087-2418556:-LUADBX.795EER1.9093e-04-0.1668image
ENSG00000127804.11,METTL16LUADGW.441756EAG2.3388e-040.1643image
ENSG00000127804.11,METTL16LUSCJNJ.26854165EAG5.3212e-030.1261image
chr17:2417087-2418556:-LUSCJNJ.26854165EER7.6874e-030.1206image
ENSG00000127804.11,METTL16MESOErlotinibEAG1.0335e-020.2818image
chr17:2417087-2418556:-MESOErlotinibEER1.0335e-020.2818image
chr17:2417087-2418556:-OVBMS.536924EER2.2817e-05-0.2464image
ENSG00000127804.11,METTL16OVBMS.536924EAG1.5304e-05-0.2514image
chr17:2417087-2418556:-PAADBortezomibEER1.0765e-04-0.2910image
ENSG00000127804.11,METTL16PAADBicalutamideEAG1.3439e-04-0.2904image
chr17:2417087-2418556:-PCPGDMOGEER2.4402e-02-0.1677image
ENSG00000127804.11,METTL16PCPGDMOGEAG2.2993e-02-0.1694image
ENSG00000127804.11,METTL16PRADGemcitabineEAG2.4589e-040.1638image
chr17:2417087-2418556:-PRADGemcitabineEER2.1716e-040.1652image
ENSG00000127804.11,METTL16READAS601245EAG2.5169e-020.2321image
chr17:2417087-2418556:-READAS601245EER2.4579e-020.2330image
chr17:2417087-2418556:-SARCEpothilone.BEER1.4447e-040.2358image
ENSG00000127804.11,METTL16SARCEpothilone.BEAG1.3801e-040.2365image
chr17:2417087-2418556:-SKCMAZD6244EER4.6671e-04-0.1610image
ENSG00000127804.11,METTL16SKCMAZD6244EAG7.8800e-04-0.1545image
ENSG00000127804.11,METTL16STADCytarabineEAG1.7950e-020.1236image
chr17:2417087-2418556:-STADCytarabineEER1.8017e-020.1236image
chr17:2417087-2418556:-TGCTGW.441756EER2.0636e-040.2929image
ENSG00000127804.11,METTL16TGCTGW.441756EAG2.6090e-040.2884image
chr17:2417087-2418556:-THCAA.770041EER3.5057e-070.2248image
ENSG00000127804.11,METTL16THCAA.770041EAG3.6452e-070.2245image
ENSG00000127804.11,METTL16THYMBI.D1870EAG3.0553e-030.2705image
chr17:2417087-2418556:-THYMBI.D1870EER1.8265e-030.2840image
ENSG00000127804.11,METTL16UCECDocetaxelEAG7.0148e-040.2552image
chr17:2417087-2418556:-UCECDocetaxelEER7.6799e-040.2541image
chr17:2417087-2418556:-UCSCGP.60474EER4.8704e-03-0.3743image
ENSG00000127804.11,METTL16UCSCGP.60474EAG6.2153e-03-0.3645image
ENSG00000127804.11,METTL16UVMAZD6244EAG1.6740e-04-0.4087image
chr17:2417087-2418556:-UVMAZD6244EER1.1808e-04-0.4172image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType